APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Peptic Ulcer Drugs

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Selected research

Market Analysis & Forecast

Global Anti-Peptic Ulcer Drugs Market Analysis and Forecast 2026-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchAnti-Peptic Ulcer Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Peptic Ulcer Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-Peptic Ulcer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Peptic Ulcer Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Peptic Ulcer Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.

In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).

Read the full market overview

Report Includes

This report presents an overview of global market for Anti-Peptic Ulcer Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-Peptic Ulcer Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-Peptic Ulcer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Peptic Ulcer Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Peptic Ulcer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-Peptic Ulcer Drugs revenue, projected growth trends, production technology, application and end-user industry.

Anti-Peptic Ulcer Drugs Segment by Company

AstraZeneca

Ask-pharm

Takeda

Yangtze River Pharm

Shandong Luoxin

Huadong Medicine

Changzhou Siyao

Beijing Yuekang

Guangdong Dahua

Xian Janssen

Anti-Peptic Ulcer Drugs Segment by Type

Proton Pump Inhibitors (PPIs)

Potassium-Competitive Acid Blockers (P-CAB)

Antacids

H2 Antagonists

Ulcer Protective Drugs

Anti-Peptic Ulcer Drugs Segment by Application

Gastritis

Gastric Ulcers

Duodenal Ulcers

Gastroesophageal Reflux Disease (GERD)

Anti-Peptic Ulcer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Peptic Ulcer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Peptic Ulcer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Peptic Ulcer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti-Peptic Ulcer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti-Peptic Ulcer Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Peptic Ulcer Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Peptic Ulcer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Proton Pump Inhibitors (PPIs) Major Player Table 3. Potassium-Competitive Acid Blockers (P-CAB) Major Player Table 4. Antacids Major Player Table 5. H2 Antagonists Major Player Table 6. Ulcer Protective Drugs Major Player Table 7. Global Anti-Peptic Ulcer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Gastritis Major Player Table 9. Gastric Ulcers Major Player Table 10. Duodenal Ulcers Major Player Table 11. Gastroesophageal Reflux Disease (GERD) Major Player Table 12. Anti-Peptic Ulcer Drugs Industry Trends Table 13. Anti-Peptic Ulcer Drugs Industry Drivers Table 14. Anti-Peptic Ulcer Drugs Industry Opportunities and Challenges Table 15. Anti-Peptic Ulcer Drugs Industry Restraints Table 16. Global Anti-Peptic Ulcer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Anti-Peptic Ulcer Drugs Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Anti-Peptic Ulcer Drugs Market Share by Region (2021-2026) Table 19. Global Anti-Peptic Ulcer Drugs Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Anti-Peptic Ulcer Drugs Market Share by Region (2027-2032) Table 21. Global Anti-Peptic Ulcer Drugs Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Players (2021-2026) Table 23. Global Anti-Peptic Ulcer Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Anti-Peptic Ulcer Drugs Key Players Headquarters & Area Served Table 25. Global Anti-Peptic Ulcer Drugs Players, Product Type & Application Table 26. Global Anti-Peptic Ulcer Drugs Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Anti-Peptic Ulcer Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Anti-Peptic Ulcer Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Type (2027-2032) Table 34. Global Anti-Peptic Ulcer Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Application (2021-2026) Table 38. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Application (2027-2032) Table 39. AstraZeneca Company Information Table 40. AstraZeneca Business Overview Table 41. AstraZeneca Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. AstraZeneca Anti-Peptic Ulcer Drugs Product Portfolio Table 43. AstraZeneca Recent Development Table 44. Ask-pharm Company Information Table 45. Ask-pharm Business Overview Table 46. Ask-pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Ask-pharm Anti-Peptic Ulcer Drugs Product Portfolio Table 48. Ask-pharm Recent Development Table 49. Takeda Company Information Table 50. Takeda Business Overview Table 51. Takeda Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Takeda Anti-Peptic Ulcer Drugs Product Portfolio Table 53. Takeda Recent Development Table 54. Yangtze River Pharm Company Information Table 55. Yangtze River Pharm Business Overview Table 56. Yangtze River Pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Yangtze River Pharm Anti-Peptic Ulcer Drugs Product Portfolio Table 58. Yangtze River Pharm Recent Development Table 59. Shandong Luoxin Company Information Table 60. Shandong Luoxin Business Overview Table 61. Shandong Luoxin Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Shandong Luoxin Anti-Peptic Ulcer Drugs Product Portfolio Table 63. Shandong Luoxin Recent Development Table 64. Huadong Medicine Company Information Table 65. Huadong Medicine Business Overview Table 66. Huadong Medicine Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Huadong Medicine Anti-Peptic Ulcer Drugs Product Portfolio Table 68. Huadong Medicine Recent Development Table 69. Changzhou Siyao Company Information Table 70. Changzhou Siyao Business Overview Table 71. Changzhou Siyao Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Changzhou Siyao Anti-Peptic Ulcer Drugs Product Portfolio Table 73. Changzhou Siyao Recent Development Table 74. Beijing Yuekang Company Information Table 75. Beijing Yuekang Business Overview Table 76. Beijing Yuekang Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Beijing Yuekang Anti-Peptic Ulcer Drugs Product Portfolio Table 78. Beijing Yuekang Recent Development Table 79. Guangdong Dahua Company Information Table 80. Guangdong Dahua Business Overview Table 81. Guangdong Dahua Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Guangdong Dahua Anti-Peptic Ulcer Drugs Product Portfolio Table 83. Guangdong Dahua Recent Development Table 84. Xian Janssen Company Information Table 85. Xian Janssen Business Overview Table 86. Xian Janssen Anti-Peptic Ulcer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Xian Janssen Anti-Peptic Ulcer Drugs Product Portfolio Table 88. Xian Janssen Recent Development Table 89. North America Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 90. North America Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 91. North America Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 92. North America Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 93. North America Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 95. North America Anti-Peptic Ulcer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 96. Europe Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 97. Europe Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 98. Europe Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 99. Europe Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 100. Europe Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Europe Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 102. Europe Anti-Peptic Ulcer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 103. China Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 104. China Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 105. China Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 106. China Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 108. Asia Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 109. Asia Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 110. Asia Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Anti-Peptic Ulcer Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Asia Anti-Peptic Ulcer Drugs Revenue by Region (US$ Million) & (2021-2026) Table 113. Asia Anti-Peptic Ulcer Drugs Revenue by Region (US$ Million) & (2027-2032) Table 114. SAMEA Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. SAMEA Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. SAMEA Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. SAMEA Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 120. SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Anti-Peptic Ulcer Drugs Image Figure 2. Global Anti-Peptic Ulcer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Peptic Ulcer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Proton Pump Inhibitors (PPIs) Image Figure 5. Potassium-Competitive Acid Blockers (P-CAB) Image Figure 6. Antacids Image Figure 7. H2 Antagonists Image Figure 8. Ulcer Protective Drugs Image Figure 9. Global Anti-Peptic Ulcer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Anti-Peptic Ulcer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Gastritis Image Figure 12. Gastric Ulcers Image Figure 13. Duodenal Ulcers Image Figure 14. Gastroesophageal Reflux Disease (GERD) Image Figure 15. Global Anti-Peptic Ulcer Drugs Market Size (US$ Million) & (2021-2032) Figure 16. Global Anti-Peptic Ulcer Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Anti-Peptic Ulcer Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Anti-Peptic Ulcer Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Anti-Peptic Ulcer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Anti-Peptic Ulcer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Anti-Peptic Ulcer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Anti-Peptic Ulcer Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Anti-Peptic Ulcer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032) Figure 28. North America Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032) Figure 29. North America Anti-Peptic Ulcer Drugs Revenue Share by Country (2021-2032) Figure 30. United States Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Anti-Peptic Ulcer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032) Figure 35. Europe Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032) Figure 36. Europe Anti-Peptic Ulcer Drugs Revenue Share by Country (2021-2032) Figure 37. Germany Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Anti-Peptic Ulcer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032) Figure 47. China Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Anti-Peptic Ulcer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032) Figure 50. Asia Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Anti-Peptic Ulcer Drugs Revenue Share by Region (2021-2032) Figure 52. Japan Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Anti-Peptic Ulcer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032) Figure 60. SAMEA Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032) Figure 61. SAMEA Anti-Peptic Ulcer Drugs Revenue Share by Country (2021-2032) Figure 62. Brazil Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Anti-Peptic Ulcer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Proton Pump Inhibitors (PPIs)
  • Potassium-Competitive Acid Blockers (P-CAB)
  • Antacids
  • H2 Antagonists
  • Ulcer Protective Drugs
Applications
  • Gastritis
  • Gastric Ulcers
  • Duodenal Ulcers
  • Gastroesophageal Reflux Disease (GERD)
Companies covered
  • AstraZeneca
  • Ask-pharm
  • Takeda
  • Yangtze River Pharm
  • Shandong Luoxin
  • Huadong Medicine
  • Changzhou Siyao
  • Beijing Yuekang
  • Guangdong Dahua
  • Xian Janssen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-Peptic Ulcer Drugs Market by Type
  3. 1.2.1 Global Anti-Peptic Ulcer Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Proton Pump Inhibitors (PPIs)
  5. 1.2.3 Potassium-Competitive Acid Blockers (P-CAB)
  6. 1.2.4 Antacids
  7. 1.2.5 H2 Antagonists
  8. 1.2.6 Ulcer Protective Drugs
  9. 1.3 Anti-Peptic Ulcer Drugs Market by Application
  10. 1.3.1 Global Anti-Peptic Ulcer Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Gastritis
  12. 1.3.3 Gastric Ulcers
  13. 1.3.4 Duodenal Ulcers
  14. 1.3.5 Gastroesophageal Reflux Disease (GERD)
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Anti-Peptic Ulcer Drugs Market Dynamics
  1. 2.1 Anti-Peptic Ulcer Drugs Industry Trends
  2. 2.2 Anti-Peptic Ulcer Drugs Industry Drivers
  3. 2.3 Anti-Peptic Ulcer Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Peptic Ulcer Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti-Peptic Ulcer Drugs Market Perspective (2021-2032)
  2. 3.2 Global Anti-Peptic Ulcer Drugs Growth Trends by Region
  3. 3.2.1 Global Anti-Peptic Ulcer Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-Peptic Ulcer Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti-Peptic Ulcer Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti-Peptic Ulcer Drugs Revenue by Players
  2. 4.1.1 Global Anti-Peptic Ulcer Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti-Peptic Ulcer Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti-Peptic Ulcer Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-Peptic Ulcer Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti-Peptic Ulcer Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Anti-Peptic Ulcer Drugs Players, Product Type & Application
  8. 4.5 Global Anti-Peptic Ulcer Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti-Peptic Ulcer Drugs Market CR5 and HHI
  11. 4.6.3 2025 Anti-Peptic Ulcer Drugs Tier 1, Tier 2, and Tier 3
5 Anti-Peptic Ulcer Drugs Market Size by Type
  1. 5.1 Global Anti-Peptic Ulcer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Anti-Peptic Ulcer Drugs Revenue Market Share by Type (2021-2032)
6 Anti-Peptic Ulcer Drugs Market Size by Application
  1. 6.1 Global Anti-Peptic Ulcer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Anti-Peptic Ulcer Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca Anti-Peptic Ulcer Drugs Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 Ask-pharm
  8. 7.2.1 Ask-pharm Company Information
  9. 7.2.2 Ask-pharm Business Overview
  10. 7.2.3 Ask-pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ask-pharm Anti-Peptic Ulcer Drugs Product Portfolio
  12. 7.2.5 Ask-pharm Recent Developments
  13. 7.3 Takeda
  14. 7.3.1 Takeda Company Information
  15. 7.3.2 Takeda Business Overview
  16. 7.3.3 Takeda Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Takeda Anti-Peptic Ulcer Drugs Product Portfolio
  18. 7.3.5 Takeda Recent Developments
  19. 7.4 Yangtze River Pharm
  20. 7.4.1 Yangtze River Pharm Company Information
  21. 7.4.2 Yangtze River Pharm Business Overview
  22. 7.4.3 Yangtze River Pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Yangtze River Pharm Anti-Peptic Ulcer Drugs Product Portfolio
  24. 7.4.5 Yangtze River Pharm Recent Developments
  25. 7.5 Shandong Luoxin
  26. 7.5.1 Shandong Luoxin Company Information
  27. 7.5.2 Shandong Luoxin Business Overview
  28. 7.5.3 Shandong Luoxin Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Shandong Luoxin Anti-Peptic Ulcer Drugs Product Portfolio
  30. 7.5.5 Shandong Luoxin Recent Developments
  31. 7.6 Huadong Medicine
  32. 7.6.1 Huadong Medicine Company Information
  33. 7.6.2 Huadong Medicine Business Overview
  34. 7.6.3 Huadong Medicine Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Huadong Medicine Anti-Peptic Ulcer Drugs Product Portfolio
  36. 7.6.5 Huadong Medicine Recent Developments
  37. 7.7 Changzhou Siyao
  38. 7.7.1 Changzhou Siyao Company Information
  39. 7.7.2 Changzhou Siyao Business Overview
  40. 7.7.3 Changzhou Siyao Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Changzhou Siyao Anti-Peptic Ulcer Drugs Product Portfolio
  42. 7.7.5 Changzhou Siyao Recent Developments
  43. 7.8 Beijing Yuekang
  44. 7.8.1 Beijing Yuekang Company Information
  45. 7.8.2 Beijing Yuekang Business Overview
  46. 7.8.3 Beijing Yuekang Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Beijing Yuekang Anti-Peptic Ulcer Drugs Product Portfolio
  48. 7.8.5 Beijing Yuekang Recent Developments
  49. 7.9 Guangdong Dahua
  50. 7.9.1 Guangdong Dahua Company Information
  51. 7.9.2 Guangdong Dahua Business Overview
  52. 7.9.3 Guangdong Dahua Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Guangdong Dahua Anti-Peptic Ulcer Drugs Product Portfolio
  54. 7.9.5 Guangdong Dahua Recent Developments
  55. 7.10 Xian Janssen
  56. 7.10.1 Xian Janssen Company Information
  57. 7.10.2 Xian Janssen Business Overview
  58. 7.10.3 Xian Janssen Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Xian Janssen Anti-Peptic Ulcer Drugs Product Portfolio
  60. 7.10.5 Xian Janssen Recent Developments
8 North America
  1. 8.1 North America Anti-Peptic Ulcer Drugs Revenue (2021-2032)
  2. 8.2 North America Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti-Peptic Ulcer Drugs Revenue by Country
  11. 8.6.1 North America Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti-Peptic Ulcer Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Anti-Peptic Ulcer Drugs Revenue (2021-2032)
  2. 9.2 Europe Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti-Peptic Ulcer Drugs Revenue by Country
  11. 9.6.1 Europe Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti-Peptic Ulcer Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Anti-Peptic Ulcer Drugs Revenue (2021-2032)
  2. 10.2 China Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032)
  5. 10.3 China Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032)
  9. 10.5 China Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-Peptic Ulcer Drugs Revenue (2021-2032)
  2. 11.2 Asia Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti-Peptic Ulcer Drugs Revenue by Country
  11. 11.6.1 Asia Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti-Peptic Ulcer Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-Peptic Ulcer Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Anti-Peptic Ulcer Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti-Peptic Ulcer Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti-Peptic Ulcer Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti-Peptic Ulcer Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti-Peptic Ulcer Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti-Peptic Ulcer Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti-Peptic Ulcer Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti-Peptic Ulcer Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti-Peptic Ulcer Drugs Revenue by Country
  11. 12.6.1 SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti-Peptic Ulcer Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst